Skip to Main content Skip to Navigation
Journal articles

Redifferentiation-facilitated radioiodine therapy in thyroid cancer

Abstract : Based on experimental data, the inhibition of the MAPkinase pathway in patients with radioiodine-refractory thyroid cancer was capable of inducing a redifferentiation. Preliminary data obtained in a small series of patients were encouraging and this strategy might become an alternative treatment in those patients with a druggable mutation that induces a stimulation of the MAP kinase pathway. This is an active field of research to answer many still unresolved questions.
Complete list of metadata

https://hal-cnrs.archives-ouvertes.fr/hal-03445754
Contributor : Corinne Dupuy Connect in order to contact the contributor
Submitted on : Thursday, November 25, 2021 - 8:18:33 AM
Last modification on : Friday, November 26, 2021 - 3:41:02 AM

File

ERCREIFFERENTIATION_24122020_N...
Files produced by the author(s)

Identifiers

Citation

Livia Lamartina, Nadège Anizan, Corinne Dupuy, Sophie Leboulleux, Martin Schlumberger. Redifferentiation-facilitated radioiodine therapy in thyroid cancer. Endocrine-Related Cancer, BioScientifica, 2021, 28 (10), pp.T179-T191. ⟨10.1530/ERC-21-0024⟩. ⟨hal-03445754⟩

Share

Metrics

Record views

13

Files downloads

6